The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in Fiercebiotech.com
IceCure Medical’s tumor-freezing treatment ProSense has nabbed FDA approval, making it the first medical device of its kind to be endorsed for the local treatment of breast cancer.
The Israeli medical technology company saw its shares jump more than 17% afterhours Friday, Oct. 3, after the company announced the approval. Shares lost some of their gains by Monday morning and were trading up about 8% from Friday’s close.
Treatment with ProSense involves a minimally invasive outpatient procedure that aims to destroy tumors by freezing them, all without the need for surgical removal of breast tissue. This approach also allows for “excellent” cosmetic results and “minimal” scarring, according to IceCure.
IceCure Medical was founded by Technion – Israel Institute of Technology alumnus Hezi Himmelfarb.